1. 160 AKT and/or mTOR inhibition as a potential target in trastuzumab resistant breast cancer cells with MUC-4 overexpression. (September 2015) Authors: Perez-Fidalgo, J.A.; Espin, E.; Tormo, E.; Pineda, B.; Cejalvo, J.M.; Sabbaghi, M.A.; Alonso, E.; Rovira, A.; Rojo, F.; Albanell, J.; Bermejo, B.; Burgues, O.; Lluch, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1910 Genomic Prognostic Profile (PAM50) and clinical-pathological characteristics in breast cancer: A prospective description of the associations found in clinical practicez. (September 2015) Authors: Gonzalez-Rivera, M.; Daoud, L.; Picornell, A.; Duran, E.; Ocana, I.; Andres, S.; Ramos-Medina, R.; Jerez, Y.; Lopez-Tarruella, S.; Rojo, F.; Martin, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combining electrokinetic transport and bioremediation for enhanced removal of crude oil from contaminated marine sediments: Results of a long-term, mesocosm-scale experiment. (15th June 2019) Authors: Cappello, S.; Cruz Viggi, C.; Yakimov, M.; Rossetti, S.; Matturro, B.; Molina, L.; Segura, A.; Marqués, S.; Yuste, L.; Sevilla, E.; Rojo, F.; Sherry, A.; Mejeha, O.K.; Head, I.M.; Malmquist, L.; Christensen, J.H.; Kalogerakis, N.; Aulenta, F. Journal: Water research Issue: Volume 157(2019) Page Start: 381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P006 Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06). (April 2023) Authors: González-Santiago, S.; Gil-Gil, M.; Carrasco, E.; Martínez-Jáñez, N.; Adamo, B.; Antolín, S.; Alonso, J.L.; Vethencourt, A.; Martínez-Vila, C.; Galve, E.; Rojo, F.; Caballero, R.; Casas, M.; Cortazar, E.; McCulloch, L.; Vedovato, J.-C.; Martín, M. Journal: Breast Issue: Volume 68(2023) Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma. (18th March 2019) Authors: Nájera, L.; Alonso‐Juarranz, M.; Garrido, M.; Ballestín, C.; Moya, L.; Martínez‐Díaz, M.; Carrillo, R.; Juarranz, A.; Rojo, F.; Cuezva, J.M.; Rodríguez‐Peralto, J.L. Journal: British journal of dermatology Issue: Volume 181:Number 1(2019) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma. (1st July 2019) Authors: Nájera, L.; Alonso‐Juarranz, M.; Garrido, M.; Ballestín, C.; Moya, L.; Martínez‐Díaz, M.; Carrillo, R.; Juarranz, A.; Rojo, F.; Cuezva, J.M.; Rodríguez‐Peralto, J.L. Journal: British journal of dermatology Issue: Volume 181:Number 1(2019) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma4. (18th March 2019) Authors: Nájera, L.; Alonso‐Juarranz, M.; Garrido, M.; Ballestín, C.; Moya, L.; Martínez‐Díaz, M.; Carrillo, R.; Juarranz, A.; Rojo, F.; Cuezva, J.M.; Rodríguez‐Peralto, J.L. Journal: British journal of dermatology Issue: Volume 181:Number 1(2019) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prognostic metabolic markers in cutaneous melanoma. (1st July 2019) Authors: Nájera, L.; Alonso‐Juarranz, M.; Garrido, M.; Ballestín, C.; Moya, L.; Martínez‐Díaz, M.; Carrillo, R.; Juarranz, A.; Rojo, F.; Cuezva, J.M.; Rodríguez‐Peralto, J.L. Journal: British journal of dermatology Issue: Volume 181:Number 1(2019) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER). (January 2022) Authors: Albanell, J.; Martínez, M.T.; Ramos, M.; O'Connor, M.; de la Cruz-Merino, L.; Santaballa, A.; Martínez-Jañez, N.; Moreno, F.; Fernández, I.; Alarcón, J.; Virizuela, J.A.; de la Haba-Rodríguez, J.; Sánchez-Rovira, P.; González-Cortijo, L.; Margelí, M.; Sánchez-Muñoz, A.; Antón, A.; Casas, M.; Beza... Journal: European journal of cancer Issue: Volume 161(2022) Page Start: 26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Targeting the PI3K/AKT/mTOR pathway with a dual mTORC1/2 inhibitor in bladder cancer. Rationale for its testing in clinical trials. (July 2016) Authors: Hernández-Prat, A.; Martinez, A.; Arpí, O.; Menéndez, S.; Iarchoukc, N.; Rojo, F.; Albanell, J.; Brake, R.; Rovira, A.; Bellmunt, J. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗